Daily Stock List
Broadcast International, Inc. (BCST)
SmarTrend Newsletters reported last week on Broadcast International, Inc. (BCST), OTCPicks, FeedBlitz did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, Broadcast International, Inc. is a leading provider of video-powered broadcast solutions. The Company's patented CodecSys software is an innovative, multi-codec video compression technology, which cuts video bandwidth requirements over satellite, cable, IP and wireless networks. Broadcast International's enterprise clients use the communication networks to deliver digital signage solutions, training programs, product announcements, entertainment, and other communications to their employees and customers. Founded in 1999, the Company has their headquarters in Salt Lake City, Utah.
Broadcast International has had consistent success for almost three decades in building and managing private satellite networks and providing video, audio and web broadcasting solutions to businesses around the world. The Company's video-powered broadcast solutions include IP, digital satellite, Internet streaming as well as other kinds of wired/wireless network distribution.
Their Video Software Solutions include The CodecSys Video Solution; CodecSys Encoder/Transcoder, and Codecsys Media Server. Their Managed Media Services include BI Networks, Digital Signage, Music & Video, and Video Production.
Through cutting bandwidth needs, their CodecSys enables a new generation of rich-media applications. The software-based CodecSys Media Server streams media content from one unified source to multiple clients and devices. The server extends and enhances a broadcaster's content delivery options. It opens new over-the-top (OTT) television opportunities to the broad array of new video-capable devices. These include PCs, cell phones, tablets, set top boxes and smart TVs.
Today, Broadcast International reported financial results for the fiscal year ended December 31, 2012. Revenue was $7.5 million, in comparison to $8.4 million in 2011. The decrease was mainly because of fewer expansion sites installed for their largest digital signage customer.
Gross profit was a record $2.7 million or 36 percent of total revenue. This represents an improvement from $2.6 million or 31 percent of total revenue in 2011. Total operating expenses decreased 17 percent to $8.8 million from $10.6 million in 2011. Net income totaled $1.6 million or $0.02 per diluted share. This is in comparison to $1.3 million or $0.02 per diluted share in 2011.
Broadcast International, Inc. (BCST), closed Wednesday at $0.109, up 28.24%, on 491,771 volume with 35 trades. The average volume for the last 60 days is 94,724 and the stock's 52-week low/high is $0.0475/$0.50.
Reliance Bancshares, Inc. (RLBS)
We are reporting on Reliance Bancshares, Inc. (RLBS) today, here at the QualityStocks Daily Newsletter.
Founded in 1999, Reliance Bancshares, Inc. is a Missouri bank holding company headquartered in Frontenac, Missouri. They provide a complete range of banking services to individual and corporate customers. Currently, Reliance Bancshares operates 20 branches in the St. Louis metropolitan area under the name of Reliance Bank.
In addition, the Company also owns and operates Reliance Bank, FSB, located in Fort Myers, Florida, with three branches in the Southwest Florida region. Reliance Bancshares lists on the OTC Markets' OTCQB.
Concerning Reliance Bancshares corporate structure, Reliance Bank (MO) is their Commercial Bank. Reliance Bank, FSB (FL) is their Savings Bank.
Reliance Bancshares deposit products include interest bearing transaction and savings accounts, demand deposits, time deposits, certificates of deposit, as well as noninterest-bearing deposits. Their loan products portfolio consists of commercial loans; real estate loans, including commercial real estate, residential real estate, and construction loans; and secured and unsecured consumer and other loans, and overdrafts.
Concerning their most recent earnings reports, this past November, Reliance Bancshares announced their third quarter earnings, which ended September 30, 2012. The Company reported net income of $274,000 for the third quarter of 2012. This is in comparison to a $4.2 million net loss for the third quarter of 2011. The improvement is mainly attributable to substantial progress made in reducing the level of problem loans. This allowed for a significant reduction in provision for loan losses; they declined by $5.1 million (99.8 percent) and $13.2 million (77.2 percent) for the quarter and year-to-date, respectively.
The Company also reduced their year-to-date net loss to $550,000. This is versus a net loss of $17.6 million for the same period of the prior year (2011). Reserves for possible loan losses as a percentage of loans increased to 4.91 percent on September 30, 2012, in comparison to 4.35 percent on December 31, 2011. Contributing to this increase, Reliance Bancshares made significant progress in obtaining recoveries from previously charged-off loans. For the third quarter 2012, they had net recoveries of $673,000.
Reliance Bancshares, Inc. (RLBS), closed Wednesday's trading at $1.26, up 26.00%, on 19,535 volume with 8 trades. The average volume for the last 60 days is 3,553 and the stock's 52-week low/high is $0.32/$1.15.
Moly Mines Ltd. (MOL.TO)
PennyStockDD reported previously on Moly Mines Ltd. (MOL.TO), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Moly Mines Ltd. engages in the exploration, development, and mining of mineral resources - primarily in Australia. The Company is mining Iron Ore in Western Australia – 170 km east of Port Hedland. Moly Mines is currently focusing on merger and acquisitions of near term production opportunities that can be financed independently. The Company's shares trade on the Toronto Stock Exchange. Moly Mines has their corporate headquarters in West Perth, Australia.
At the Spinifex Ridge iron-ore mine, the Company is currently mining four areas of iron-ore mineralization identified within the mining leases granted and acquired for the Spinifex Ridge molybdenum project. These are Auton, Auton North East, Dalek and Gallifrey (Iron Ore Project). These four are 500 m to the east of the Spinifex Ridge molybdenum-copper resource.
The Spinifex Ridge molybdenum project is on the same mining leases as the Spinifex Ridge iron-ore mine. It is development-ready with all environmental approvals received. Moly Mines reported in December 2011 that the project would be put on hold because of the continued weakness of worldwide molybdenum prices and the strength of the Australian dollar that made the project sub-economic for the short-term. The project remains on care and maintenance with tenement and permitting obligations being met.
On January 31, 2013, Moly Mines reported the highlights of their Quarterly Activities Report and Quarterly Cashflow Report for the period ending December 31, 2012. Highlights for the Company include a production and sales target at 1 million tonnes for calendar year 2013. In addition, an updated Ore Reserve estimate was completed.
Concerning Mine Performance (unaudited), 185,315 wet ore tonnes were mined for the Quarter, down 36 percent on the previous Quarter; 261,893 wet ore tonnes were sold for the Quarter, up 44 percent; 59.0 percent Fe was the average grade of ore shipped.
Gross sales revenue for the December Quarter was $23.4M, up 58 percent from the September 2012 Quarter. Operating cash costs/tonne of ore shipped was $68.9/t. Mine EBITDA for the December Quarter was $0.9 M and Ore stocks on hand was 124,000 tonnes. Cash on hand was $41.1M, down $13.4M. This was primarily because of revenue from December 2012's iron ore shipment not being received until January 2013.
Moly Mines Ltd. (MOL.TO), closed Wednesday's trading session at $0.13, up 8.33%, on 111,500 volume. The stock's 52-week low/high is $0.11/$0.28.
Pershing Gold Corp. (PGLC)
Streetwise Reports, UltimatePennyStock, Investors Online Bell, and smartOTC reported earlier on Pershing Gold Corp. (PGLC), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Based in Lakewood, Colorado, Pershing Gold Corp. is a gold and precious metals exploration company that lists on the OTCQB. They are pursuing exploration and development opportunities primarily in Nevada. The Company is currently focusing on exploration at their Relief Canyon properties, Pershing County, northwestern Nevada. The Relief Canyon Gold Mine is a 1980s-vintage gold mine located in a significant gold and silver trend. The Relief Canyon Mine property is owned by Gold Acquisition Corp., Pershing Gold's wholly owned subsidiary. Under-explored areas to the North and South of existing open-pits will undergo exploration by Pershing Gold.
The Relief Canyon Mine consists of three open-pit mines and a recently refurbished and upgraded heap leach gold ore processing facility. The mine has produced gold intermittently since 1984. It has been in a care and maintenance status for a number of years. Pershing Gold is drilling at Relief Canyon to confirm, expand, and upgrade the gold resource in order to resume mining. The Company is making strategic acquisitions of mineral targets near the Relief Canyon Mine that will allow them to control a major portion of the Pershing Gold and Silver Trend.
Pershing Gold expanded their Relief Canyon property position substantially in 2012. They accomplished this with the acquisition of the Pershing Pass and Relief Canyon Expansion properties. They acquired the former Relief Canyon Mine property in August of 2011. This includes a processing plant that they could use in mining operations if their exploration efforts are successful. Pershing Gold started an exploration drilling program in 2011.
The Relief Canyon Mine, Pershing and Relief Canyon Expansion properties are collectively called the Relief Canyon properties. The Company's intention is to continue to acquire additional mineral targets in Nevada and elsewhere where they believe they have the potential to quickly expand and advance known mineralization and the potential to discover new deposits.
Pershing Gold Corp. (PGLC), closed Wednesday's session at $0.453, up 1.80%, on 722,537 volume with 108 trades. The average volume for the last 60 days is 829,943 and the stock's 52-week low/high is $0.252/$0.62.
Resource Ventures, Inc. (REVI)
PennyStocks24, GaintheGreen, Market Bulls and The Bull Exchange reported this week on Resource Ventures, Inc. (REVI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Resource Ventures, Inc. is an independent worldwide Electrical Power Production and Petroleum Exploration Company. Their focus is on the acquisition and development of a diversified portfolio of complementary power generation and energy production projects. The Company is using traditional generating disciplines and operating in underserved areas requiring Distributed Generation. In addition, the Company has their Resources Printing & Graphics, Inc. - a wholly owned subsidiary. Resources Printing & Graphics provides printing and graphics services in the Orange County area of Southern California. Resource Ventures has their headquarters in Silverado, California.
The Company's strategic plan includes the development of grid connected, in situ generating stations backed by Investment Grade Credit on the buy side, long-term Power Purchase Agreements (PPAs) on the sell side, and solid in-country support from Government Agencies and Banking Authorities. Their strategic vision anticipates the use of modern and traditional power generation technologies in combination with different energy sources. This includes oil and natural gas and renewable energy sources such as biomass, bio-diesel, wind power and photovoltaic systems.
Moreover, Resource Ventures' plan is to go after oil & gas exploration and development opportunities in collaborations with global resource companies in an array of locations.
Recently, Resource Ventures President, Mr. Bob Thompson, announced that the Company, via their wholly owned subsidiary, Global Energy Management Ltd., signed a Letter of Intent (LOI) with a renewable energy producer in the Czech Republic for the purchase of solar power production facilities. The power generating facilities are in Central Slovakia. They have a combined production capacity of 2.7 MW and annual net cash flow of EUR 1.7 million (USD $2.2 million).
Last week, Mr. Thompson announced that Global Energy Management signed a Letter of Intent (LOI) anticipating a series of Joint Ventures with Next Space Solutions, LLC of California. The Joint Ventures referenced in the LOI include multiple renewable power production assets in California totaling 50 MW. The first proposed Joint Venture is the acquisition and development of a photovoltaic project with an estimated $2 million value.
Resource Ventures, Inc. (REVI), closed Wednesday's trading session at $0.0489, up 39.71%, on 1,619,334 volume with 96 trades. The average volume for the last 60 days is 1,052,038 and the stock's 52-week low/high is $0.012/$2.14.
Uranerz Energy Corp. (URZ)
SmarTrend Newsletters, Top Stock Analysts, and Streetwise Reports reported recently on Uranerz Energy Corp. (URZ), The Street, Oakshire News Bulletin, Investor Spec Sheet, Greenbackers did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Casper, Wyoming, Uranerz Energy Corp. is a mining company focusing on near term commercial in-situ recovery (ISR) uranium production. Currently, the Company is building their first ISR mine in the Powder River Basin of Wyoming (The Nichols Ranch ISR Uranium Project). The expectation is that the Nichols Ranch ISR Uranium Project will become the first new uranium mine built in Wyoming since 1996. Uranerz Energy has a processing agreement with Cameco and has entered into long-term uranium sales contracts for a portion of their planned production with two of the largest nuclear utilities in America, including Exelon.
In-situ recovery (ISR) is a mining process that uses a leaching solution to extract uranium from sandstone-hosted uranium deposits. It is the generally accepted extraction technology used in the Powder River Basin. The Powder River Basin of Wyoming is an area well known for hosting uranium-mineralized roll fronts that are amenable to ISR mining techniques.
Uranerz Energy has a number of advanced-stage projects located in the Pumpkin Buttes Mining District of the central Powder River Basin. The Nichols Ranch ISR Uranium Project has licensing for a capacity of 2 million pounds per year of uranium yellowcake, with an initial target production rate of 600,000 to 800,000 pounds per year, following a ramp up period. Construction of the central processing plant and installation of the environmental monitor and production wells for ISR mining are proceeding with completion targeted for this calendar year.
In October 2012, Uranerz Energy announced that the Wyoming Department of Environmental Quality issued the Class I Underground Injection Control (deep disposal well) permit for the Company's Nichols Ranch ISR Uranium Project in the Powder River Basin. This deep disposal well authorization is the last permit required to start operations and commercial uranium production at Nichols Ranch. The Company has now received all federal and Wyoming State permits for Nichols Ranch mine production. The project will also serve as a platform to develop Uranerz Energy's other Powder River Basin properties with enhanced economics for adjacent and satellite projects.
Uranerz Energy Corp. (URZ), closed Wednesday's trading session at $1.10, down 5.17%, on 553,457 volume with 958 trades. The average volume for the last 60 days is 293,399 and the stock's 52-week low/high is $1.08/$2.56.
Clean Coal Technologies, Inc. (CCTC)
PennyTrader Publisher, OTCJournal, and Greenbackers reported earlier on Clean Coal Technologies, Inc. (CCTC), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in New York, New York, Clean Coal Technologies, Inc. holds patented process technology and other intellectual property (IP) that converts raw coal into a cleaner burning fuel. Their trademarked products, Pristine™ and Pristine-M™, are significantly more efficient, less polluting, more cost-effective, and provide more heat than untreated coal. Clean Coal Technologies lists on the OTC Markets'
Use of the Company's unique process makes possible the upgrade of low-rank coals, including lignite, into premium fuels that are high in calorific content and low in pollutants. The basis of the principal elements of their pre combustion technology is on well-proven science and tried-and-tested industrial components. Their clean coal technology may reduce approximately 90 percent of chemical pollutants from coal, including Sulfur and Mercury. As a result, this would resolve emissions issues affecting coal-fired power plants.
Clean Coal Technologies, together with Archean Group, the Company's partner in Good Coal Pte, Ltd, is working with Science Applications International Corporation (SAIC) on the construction of a 1:10 scale pilot plant. The plant will undergo testing at the site of a major U.S coal-fired power company in the State of Oklahoma. Tests are taking place to complete the final design of the key components of the plant. The pilot plant is on track for commissioning this year.
In February, Clean Coal Technologies announced that they signed a new EPC Agreement with Science Applications International Corporation (SAIC) following the termination of the Good Coal Pte joint venture. They also remitted the first payment of $2 million to SAIC for the construction of the 2-ton/hour pilot plant in Oklahoma, as per the terms of the new contract. The expectation is that the Commissioning of the pilot plant will take place during the second quarter of this year. As sole counterparty to the new EPC contract, Clean Coal Technologies has assumed the obligations for the project under the contract; they will own the completed pilot plant outright.
Last week, Clean Coal Technologies announced an agreement for a $400,000 advance payment from Singapore-based Ventrillion Management Company Ltd. The Company will issue 8 million shares for this $400,000. The issuance is pursuant to an amendment to Clean Coal Technologies' previously announced definitive agreement with Ventrillion for the private placement of up to 300 million common shares of Clean Coal in exchange for up to $15 million. It is considered an advance on the second tranche of capital.
Clean Coal Technologies, Inc. (CCTC), closed today at $0.0598, up 4.91%, on 157,461 volume with 18 trades. The average volume for the last 60 days is 733,254 and the stock's 52-week low/high is $0.04/$0.0999.
Generex Biotechnology Corp. (GNBT)
OTCPicks, PennyTrader Publisher, and Greenbackers reported previously on Generex Biotechnology Corp. (GNBT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Based in Toronto, Ontario, Generex Biotechnology Corp. engages in the research, development, and commercialization of drug delivery systems and technologies. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity - with no deposit in the lungs. Generex Biotechnology's proprietary liquid formulations allow drugs normally administered by injection to undergo absorption into the body through the lining of the inner mouth using the Company's proprietary RapidMist™ device.
Antigen Express, Inc. is a wholly owned subsidiary of Generex Biotechnology. Antigen Express is a platform technology and product-based company. This subsidiary is developing proprietary vaccine formulations for active immunotherapy and disease prevention. The core platform technologies of Antigen Express consist of immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.
Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One technology focuses on modification of peptides with Ii-Key to increase potency. A second technology relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for powerful stimulation of T-helper cells and prevents the further growth of cancer cells.
Generex Biotechnology is positioned to move ahead with their clinical and regulatory programs and corporate plans. Generex is actively seeking prospective partners for the Phase III trial of the Antigen Express AE37 breast cancer vaccine. Antigen Express is preparing to seek a Special Protocol Assessment (SPA) for the trial. An SPA is a declaration from the Food and Drug Administration (FDA) that the trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval.
Today, Generex Biotechnology commented on the results of the meeting of their stockholders held on March 28, 2013. On April 1, 2013, the Company filed a Form 8-K Current Report with the United States Securities and Exchange Commission detailing the voting results in respect of each of the proposals put forward at the meeting. The line up of directors put forward in Generex' proxy statement in respect of the meeting was elected.
Furthermore, the proposals to amend their Restated Certificate of Incorporation to increase the number of shares of common stock authorized, and authorize the Board to effect a reverse stock split of their common stock (up until September 27, 2014), were approved by holders of a majority of their outstanding stock. The proposal to amend their stock plan by increasing the number of shares of common stock available was also approved by Generex' stockholders.
Generex Biotechnology Corp. (GNBT), closed Wednesday's trading session at $0.0309, up 3.00%, on 1,075,982 volume with 70 trades. The average volume for the last 60 days is 1,337,137 and the stock's 52-week low/high is $0.0205/$0.1438.
Rainbow Coral Corp. (RBCC)
The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.13, up 8.33%, on 328,022 volume with 50 trades. The stock’s average daily volume over the past 60 days is 159,917, and its 52-week low/high is $0.10/$2.67.
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer
Rainbow Coral Corp. Company Blog
Rainbow Coral Corp. News:
RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow
RBCC TheraKine Joint Venture Offers Significant Opportunity in Licensing
RBCC Forms Joint Venture With Cutting-Edge Drug Delivery Company TheraKine
Loans4Less.com, Inc. (LFLS)
The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.11, up 10.00%, on 18,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 5,771, and its 52-week low/high is $0.01/$0.39.
Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.
Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.
The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.
Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer
Loans4Less.com, Inc. Company Blog
Loans4Less.com, Inc. News:
Loans4Less.com Expects to Achieve Fully Reporting Status by 2014
Loans4Less.com Launches New Advertising Campaign to Reach a Potential 1.7 Million
Loans4Less.com, Inc. - Audited Financials 2012
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.29, up 5.45%, on 41,922 volume with 14 trades. The stock’s average daily volume over the past 60 days is 205,366, and its 52-week low/high is $0.161/$0.55.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Announces Fourth Quarter 2012 Financial Results and Provides Business Update
International Stem Cell Corp. to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and Provide Business Update
International Stem Cell Corp. to Host Conference Call on Friday, March 22 to Discuss Positive Study Data of Parkinson's Disease
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.098, up 2.08%, on 2,276,965 volume with 74 trades. The stock’s average daily volume over the past 60 days is 4,446,116, and its 52-week low/high is $0.0275/$0.155.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Trials Workshop
Advaxis Nominated for Best Early-Stage Vaccine Biotech at 6th Annual Vaccine Industry Excellence Awards
Advaxis’ ADXS-cHER2 Immunotherapy Researchers Receive Penn One Health Award for Initiatives in Canine Osteosarcoma
ADXS tried to make a move on Monday as the stock consolidates following a climb of more than 400 percent. The move didn’t follow through on Tuesday, but the chart is on radar for increased activity with the stock price back over the 50-dma.
To view the video chart, visit the following link: http://www.qualitystocks.net/videocharts
Although global warming is considered by most people to be a subject of fairly recent interest, at least at the national and global level, the fact is that concerns about the contribution of human activity to global warming appeared in U.S. government statements over 50 years ago, during the Johnson administration.
A recent article by David Hone, published in the The Energy Collective (http://dtg.fm/d25A) shows that the subject of climate change and global warming weren’t mentioned much in the popular culture until well into the 1980s. However, a report issued by a special pollution panel of the President’s Science Advisory Committee in 1965 warns of temperature rise from CO2 buildup due to the growing use of fossil fuels. The article goes further, mentioning Nobel Prize winning Swedish scientist Svante Arrhenius, who calculated back near the turn of the 20th Century possible effects of CO2 on surface temperature.
Today, concerns about global warming are not isolated to a few of the world’s scientists, but rather reverberate around the globe as nations large and small seek better ways to deal with anticipated consequences of continuing greenhouse gas emissions. The need for energy continues to grow as the world industrializes. Wind and solar power technology improves, but neither wind nor solar offers a complete solution due to serious limitations. Wind and solar are completely subject to the variations of nature, and can’t be depended upon to be fully available every time they are needed. In addition, the losses involved in storing generated electricity from such sources limit their use for automotive transportation, one of the biggest polluters.
California-based VIASPACE, a renewable energy company devoted to the use of dedicated biomass fuels, offers one of the world’s highest yielding biomass crop, Giant King Grass (GKG), a super-fast growing energy crop that successfully addresses all of the issues associated with wind, solar, and other renewable fuel solutions. It is highly cost-effective compared to other solutions, plus works with existing facilities and infrastructure, requiring minimal up-front investment. And, since GKG absorbs as much carbon during growth as emitted during burning, it has a low-to-zero carbon footprint. Unlike wind and solar, it is a fuel that can generate energy on demand, at any time of the day or night, and in any weather. Moreover, it can even be processed into green biofuels, like green gasoline, for use in industry and automobiles.
For additional information, visit www.viaspace.com
March was a busy month for VentriPoint Diagnostics, a Canadian based medical device company focused on revolutionary software for 3D heart analysis. The company was successful in completing several important steps in the development and approval of what is viewed as potentially transformative diagnostics technology.
March began with the announcement that the company had received acceptance from the FDA (U.S.) of its submission for right heart analysis in Pulmonary Arterial Hypertension (PAH), meaning that all of the required information is present for the FDA to proceed with a substantive review. PAH is a devastating disease, which can affect individuals from infancy to the elderly, offering an average patient lifespan of less than 3 years after diagnosis if untreated. Although treatment started early after detection appears to be more effective than when started later, the majority of patients with PAH continue to be diagnosed too late for treatment to be fully effective. VentriPoint has created diagnostic tools to monitor patients with heart disease, and has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure, and normal hearts.
Shortly after the positive notice from the FDA, VentriPoint announced intention to complete a private placement of up to $2 million, providing additional funds to continue progress in developing and moving its technologies to market. That was soon followed by the company’s announcement of formal application for European and Canadian approval for its database for non-specific heart disease (NRV), a database that allows clinicians to rapidly and accurately assess the status of the right ventricle (RV) in all patients that do not have significant congenital heart defects or Pulmonary Arterial Hypertension, yet may have a variety of other conditions. The company expects to have a response from the European CE Mark and Health Canada offices in the next 30 days.
For additional information, visit www.VentriPoint.com
NOHO is wasting no time kicking open every door in the beverage industry with a product that defines its own category, NOHO – The Hangover Defense™ (short for NO HangOver), which is being marketed as a functional lifestyle drink designed to “prehab” the body and compensate for drinking quantities of alcohol that would normally result in a hangover.
The company is essentially out ahead of the pack with no legitimate competition here. The next best thing in-category are a slew of useless, repackaged energy drinks that pretend to do something, while NOHO is real science based on a secret, proprietary formula designed by one of the world’s top pharmacists, Dr. David Galardi. Galardi, who was a top man over at globally recognized pharmaceutical services leader AmerisourceBergen, came up with the idea years before NOHO even contacted him about the possibility and had been basically sitting on this technology. Galardi developed the original concept during his residency while working at a local ER, where the idea sprang from an analysis of IV drip methods used to treat alcohol poisoning.
NOHO helps the body metabolize alcohol naturally by preloading the system with vital minerals, nutrients, and vitamins, shielding the body with preventive rehabilitation factors and making available what is essential for feeling better, even before the effects of drinking take their toll. Because hangovers result from consuming alcohol faster than the body can metabolize it and thus a cascade failure of hydrating factors results in the syndrome defined as alcoholic ketoacidosis, NOHO’s design as a pre-emptive attack on this cascade failure is the ultimate hangover killer.
NOHO’s powerful one-two punch dopes tissues against the deleterious effects of alcohol with vital nutrients, while simultaneously providing a fusion of concentrated extracts that speed recovery. Prickly pear helps to detoxify the liver by flushing out bio-accumulating toxins and ginger coats the stomach, relieving nausea. NOHO achieves its effect without the need for excess stimulants like caffeine and sugar, making this easy to use 2 oz. shot a real dynamo and sales already reflect this strength.
While NOHO clearly has the science and the functional validity to crush all comers, management is not resting on their laurels and has already set their sights on nothing less than total world domination in the product space. NOHO has hit the ground running with high-profile CEO of the product’s distribution arm, Dolce Bevuto LLC, Jay Grdina, making the rounds on Bloomberg TV and CNBC. NOHO is looking to capture vast global market share with a product/concept that is truly universal and the beverage has already seen huge movements domestically, as well as in European markets. Central and South America are just being cracked open and the sky is basically the limit for a company like this, whose savvy is unmistakable in moves like getting rapper Lil Jon, the king of crunk, to help endorse the product after he tweeted about his positive experience using NOHO, when a friend at a party recommended it to him.
The company is moving to land major deals with Vegas casinos, a market where NOHO has already taken off, and signed a deal with the biggest beverage distributor in Arizona (Alliance Beverage Distributing Company). The major selling point has simply been the fact that this product works. In case after case, initially skeptical consumers, in disbelief that such a product can really deliver, are generating repeat business as loyal brand followers.
This is the perfect sidecar beverage for the nightlife set and the marketing savvy displayed thus far is exactly what you want to see out of a company like DRNK. Solid audience engagement and customer retention metrics, a clear vision to grow the distribution framework across a global market, and a bold presence in the retail space all add up to making DRNK one to watch. The company is projecting sales in the $100M range and this product has the muscle to deliver on that projection because it really offers people the ability to consume alcohol, whether it’s one drink or ten, and still get up the next day, fully able to function. While the obvious nightlife market is vast, there is an even larger, less-obvious market among older professionals who are finding the product a perfect way to gain a competitive edge in keeping up with the younger executives, even after a long day of business meetings, or wining and dining important clients.
At just $3.49 a shot, the product seems almost too good to be true as a means of preventing a hangover, but that is exactly why there is so much upside potential with DRNK’s NOHO shot. Grdina has taken to the game like a fish to water and the company’s Twitter and Facebook feeds are already blazing with fan and celebrity interactions alike.
For more information on NOHO, check out their site at www.NOHOdrink.com
Today's Top 3
The QualityStocks Public Company Sponsor News